The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors
Open accessAbstract
Purpose: Owing to its exquisite chemotherapy sensitivity, most patients with metastatic germ cell tumors (GCTs) are cured with cisplatin-based chemotherapy. However, up to 30% of patients with advanced GCT exhibit cisplatin resistance, which requires intensive salvage treatment, and have a 50% risk of cancer-related death. To identify a genetic basis for cisplatin resistance, we performed whole-exome and targeted sequencing of cisplatin-sensitive and cisplatin-resistant GCTs. Methods: Men with GCT who received a cisplatin-containing chemotherapy regimen and had available tumor tissue were eligible to participate in this study. Whole-exome sequencing or targeted exon-capture–based sequencing was performed on 180 tumors. Patients were categorized as cisplatin sensitive or cisplatin resistant by using a combination of postchemotherapy parameters, including serum tumor marker levels, radiology, and pathology at surgical resection of residual disease. Results: TP53 alterations were present exclusively in cisplatin-resistant tumors and were particularly prevalent among primary mediastinal nonseminomas (72%). TP53 pathway alterations including MDM2 amplifications were more common among patients with adverse clinical features, categorized as poor risk according to the International Germ Cell Cancer Collaborative Group (IGCCCG) model. Despite this association, TP53 and MDM2 alterations predicted adverse prognosis independent of the IGCCCG model. Actionable alterations, including novel RAC1 mutations, were detected in 55% of cisplatin-resistant GCTs. Conclusion: In GCT, TP53 and MDM2 alterations were associated with cisplatin resistance and inferior outcomes, independent of the IGCCCG model. The finding of frequent TP53 alterations among mediastinal primary nonseminomas may explain the more frequent chemoresistance observed with this tumor subtype. A substantial portion of cisplatin-resistant GCTs harbor actionable alterations, which might respond to targeted therapies. Genomic profiling of patients with advanced GCT could improve current risk stratification and identify novel therapeutic approaches for patients with cisplatin-resistant disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationZhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · cited 1×
“The most common of these was MDM2 amplification, which has immediate therapeutic implications because seven potent inhibitors of MDM2 are under study in clinical trials with promising results.(15) Furthermore, sensitivity to MDM2 inhibitors is more pronounced in neuroblastoma cell lines that harborMYCN amplification,…”
Background
Cited by
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Huang, X., Li, Z., Zhang, Q., Wang, W., Li, B., Wang, L., Xu, Z., Zeng, A., Zhang, X., Zhang, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0969-3 · Cited by 476
Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Self-citationHuman germ cell tumours from a developmental perspective
Oosterhuis, J. W., & Looijenga, L. H. J. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0178-9 · Cited by 328
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K.-P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy217 · Cited by 326
Loh, K. P., & Fung, C. (2017) · Rare Tumors · doi:10.4081/rt.2017.6867 · Cited by 23
Metadata
- Authors
- Bagrodia, A., Lee, B. H., Lee, W., Cha, E. K., Sfakianos, J. P., Iyer, G., Pietzak, E. J., Gao, S. P., Zabor, E. C., Ostrovnaya, I., Kaffenberger, S. D., Syed, A., Arcila, M. E., Chaganti, R. S., Kundra, R., Eng, J., Hreiki, J., Vacic, V., Arora, K., Oschwald, D. M., Berger, M. F., Bajorin, D. F., Bains, M. S., Schultz, N., Reuter, V. E., Sheinfeld, J., Bosl, G. J., Al-Ahmadie, H. A., Solit, D. B., & Feldman, D. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-11-20
- Volume
- 34
- Issue
- 33
- Pages
- 4000-4007
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2522030015
- Cited by
- 198
- References
- 3
- FWCI
- 14.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.